References
- Joura E, Giuliano A, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira E, Ngan Y, Petersen L, Lazcano E, et al. Efficacy of a 9-valent HPV vaccine against genital infection and intraepithelial neoplasia in women. New Engl J Med 2014; 372(8):711-23; PMID: 25693011.
- Lachenbruch PA, Rida W, Kou J. Lot consistency as an equivalence problem. J Biopharm Stat 2004; 14:275-90; PMID:15206526; http://dx.doi.org/10.1081/BIP-120037179
- Marshall V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics 2011; 127 Suppl 1:S23-S30; PMID:21502242; http://dx.doi.org/10.1542/peds.2010-1722E
- US Food and Drug Administration CfBR. Guidance for industry for the evaluation of combination vaccines for preventable disease: production, testing and clinical studies. http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/UCM175909.pdf. 1997.
- World Health Organization. Clinical considerations for evaluation of vaccines for prequalification. http://www.who.int/immunization_standards/vaccine_quality_considerations_oct10.pdf. 2010.
- European Medicines Agency - Committee for human medicinal products. Note for guidance on the clinical evaluation of vaccines. http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2009/09/WC500003875.pdf. 2005.
- Wang WW, Mehrotra DV, Chan IS, Heyse JF. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006; 16:429-41; PMID:16892905; http://dx.doi.org/10.1080/10543400600719251
- Van Damme P. Immunogenicity and safety of a novel 9-valent hpv vaccine in girls 9-15 years of age compared to the quadrivalent vaccine. EUROGIN 2013, November 3-6 Available at http://www.eurogincom/2013/indexphp/abstracts/eurogin-2013-abstracts2014. Accessed January 12, 2014. 2014.
- Roberts C, Hess E, Matys K, Brown M, Haupt R, Luxembourg A, Vuocolo S, Saah A, Antonello J, Green T. Development of a human papillomavirus competitive luminex immunoassay for nine HPV types. Hum Vaccin Immunother 2014; 10(8):2174-103; PMID:25424920
- Brown MJ, Seitz H, Towne V et al. Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 21:587–593, 2014
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226.
- Ganju J, Izu A, Anemona A. Sample size for equivalence trials: a case study from a vaccine lot consistency trial. Stat Med 2008; 27:3743-54; PMID:18416439; http://dx.doi.org/10.1002/sim.3273
- Sun X, Li X, Chen J. Comments on 'Sample size for equivalence trials: a case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona. Stat Med 2012; 31:1652-3; PMID:22711252; http://dx.doi.org/10.1002/sim.4408
- Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine 2012;30 Suppl 5:F83–F87.
- Brown D, Muller M, Sehr P et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. Vaccine 32:5880–5887, 2014.